SBIR-STTR Award

High-Intensity, Collapsible Phototherapy Device for Neonatal Jaundice for Home Use
Award last edited on: 1/31/18

Sponsored Program
SBIR
Awarding Agency
NIH : NICHD
Total Award Amount
$1,149,724
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Donna Jean Brezinski

Company Information

Little Sparrows Technologies LLC

408 Highland AvenueUnit 416
Somerville, MA 01890
Location: Single
Congr. District: 07
County: Middlesex

Phase I

Contract Number: 1R43HD081745-01
Start Date: 8/15/14    Completed: 2/14/15
Phase I year
2014
Phase I Amount
$149,800
Approximately 8% of all newborns risk permanent neurotoxic brain injury due severe neonatal jaundice (SNJ). This condition, generally occurring in the first two weeks of life, is almost always cured with high- intensity blue light phototherapy In the United States, most phototherapy is delivered in a neonatal intensive care unit (NICU) or inpatient nursery because effective, high-intensity devices are designed for that environment. This current care practice has the undesirable consequence of separating mothers and babies during a developmentally vulnerable time while breastfeeding is being established. Approximately 250,000 otherwise well newborns require phototherapy each year. The annual estimated health care cost for treating SNJ in hospitals is in excess of $200 million. Little Sparrows Technologies LLC has developed the Bili-Hut' a novel, collapsible, high-intensity, radial array phototherapy device for home use. Current phototherapy devices sufficiently portable for home use do not deliver adequate phototherapy to meet the current American Academy of Pediatrics recommendations for high intensity phototherapy. Once optimized, the Bili-Hut' will meet current phototherapy standards and eliminate the need hospital readmissions for otherwise well babies. This could significantly reduce the stress to the mother-baby pair during treatment, at a substantially reduced cost. The goal of this proposal is creation of a next-stage Bili-Hut' prototype demonstrating equivalent or superior phototherapy to the market-leading NICU phototherapy device. This will fill an unmet need for an effective home care option. We will achieve this goal by comparing the Bili-Hut' efficacy against that of the Natus neoBlue(R) with a benchmark two-dimensional assay, and a novel-three dimensional baby contour assay that is expected to demonstrate the superiority of radial light delivery in maximizing body surface area exposure. An iterative design process will be influenced by these assay results so that the Bili-Hut's light array, radius of curvature and distance from patient canbe optimized for highest possible therapeutic effect. Innovations in this project include a collapsible, radial array, high intensity phototherapy device designed for home use, and a predicted relative efficacy based on a novel baby contour assay. Phase I studies will culminate in a refined prototype to guide industrial design of a device for home treatment of SNJ. Our new assay will provide a theoretical framework for designing clinical trials to test high intensity phototherapy over an increased skin area.

Thesaurus Terms:
Academy;Address;American;Area;Base;Benchmarking;Bilirubin;Biological Assay;Body Surface Area;Brain Injuries;Breast Feeding;Businesses;Caring;Characteristics;Clinical;Clinical Trials;Clinical Trials Design;Communities;Comparative;Cost;Data;Design;Development;Device Designs;Devices;Dimensions;Engineering;Environment;Experience;Family;Fda Approved;Funding;Generations;Goals;Grant;Health Care Costs;Hematologist;Home Environment;Hospital Readmission;Hospitals;Improved;Innovation;Inpatients;Isomerism;Iterative Design;Laboratories;Lead;Life;Light;Light Intensity;Lighting;Liver;Manikins;Marketing;Meetings;Mothers;Neonatal;Neonatal Intensive Care Units;Neonatal Jaundice;Neurotoxic;Newborn Infant;Novel;Nurseries;Optics;Pathway Interactions;Patient Home Care;Patients;Pediatrics;Performance;Phase;Phase 1 Study;Phototherapy;Physiological;Positioning Attribute;Preparation;Prevent;Process;Property;Prototype;Public Health Medicine (Field);Public Health Relevance;Radial;Recommendation;Relative (Related Person);Reliance;Research Clinical Testing;Risk;Safety;Serum;Shapes;Skin;Small Business Innovation Research Grant;Sparrows;Staging;Stress;Surface;Technology;Testing;Therapeutic Effect;Time;Tool;Two-Dimensional;United States;Wallaby;Water;Work;

Phase II

Contract Number: 2R44HD081745-02A1
Start Date: 8/15/14    Completed: 7/31/18
Phase II year
2016
(last award dollars: 2017)
Phase II Amount
$999,924

Approximately 10% of all newborns worldwide risk permanent neurotoxic brain injury due severe neonatal jaundice (SNJ). This condition, generally occurring in the first two weeks of life, is almost always cured with high-intensity blue light phototherapy. In the United States, most phototherapy is delivered in a neonatal intensive care unit (NICU) because effective, high-intensity devices have engineering features limiting use to that environment. This current care practice has the undesirable consequence of separating mothers and babies during a developmentally vulnerable time while breastfeeding is being established. Approximately 250,000 otherwise well newborns require phototherapy each year. The annual estimated health care costs for treating SNJ in hospitals are in excess of $300 million. Little Sparrows Technologies has developed the Bili-Hut™, a novel, portable, high-intensity, radial array phototherapy device for use at the mother's bedside in the hospital or in the home. Current phototherapy devices sufficiently portable for home use do not deliver adequate phototherapy to meet the American Academy of Pediatrics recommendations for high-intensity phototherapy. The Bili-Hut™ meets current phototherapy standards, enables treatment in a mother's post-partum room during birth hospital admission, and eliminates the need for hospital readmissions for otherwise well jaundiced babies who can be treated at home. This will eliminate the stress of separation to the mother-baby pair during treatment at a substantially reduced cost. We have achieved our Phase I goal of creation of a next-stage Bili-Hut™ that demonstrates efficacy superior to a market-leading NICU phototherapy device through increased skin exposure to therapeutic light. Our Phase II aims will develop capabilities of thermostability and improved infant eye shielding from noxious blue light exposure through an innovative, comprehensive device design. Innovations in this project include the radial Bili-Hut™ light array with reflective interior, providing superior light distribution, the first environmental temperature-modulated, high-intensity phototherapy device, the first high-intensity phototherapy device to eliminate the need for infant eye protection, and the first mother-baby friendly, high-intensity device that will enable use in the home.

Public Health Relevance Statement:
Severe neonatal jaundice is one of the most common conditions resulting in readmissions of newborns. Current care practice requires treatment in a NICU to ensure thermostability while providing high-intensity therapy. This causes stress to families and healthcare costs of >$300K annually. When fully realized, the Bili- Hut™ will address this public health concern by delivery of portable, high- intensity therapy with thermoregulation capability suitable for use at home.

NIH Spending Category:
Bioengineering; Brain Disorders; Chronic Liver Disease and Cirrhosis; Digestive Diseases; Liver Disease; Neurosciences; Patient Safety; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period

Project Terms:
Academy; Address; Admission activity; Affect; Amber; American; Area; Attenuated; attenuation; base; Bilirubin; Biological Assay; Birth; Body Surface Area; Brain Injuries; Breast Feeding; Burundi; Caring; Cerebral Palsy; Cessation of life; Clinical; Clinical Trials; cost; Data; Deafness; design; Developed Countries; Developing Countries; Development; Device Approval; Device Designs; Devices; Documentation; Encephalopathies; Engineering; Ensure; Environment; Exposure to; Eye; Family; Feces; field study; Funding; Generations; Goals; Government; Health Care Costs; Health Services Accessibility; Heating; Home environment; Hospital Readmission; Hospitals; Human; Icterus; improved; Incubators; India; Industry; Infant; innovation; Intensive Care Units; Isomerism; Life; Light; Lighting; Low Birth Weight Infant; Marketing; Masks; meetings; meter; Modification; Monitor; Mothers; Neonatal Intensive Care Units; Neonatal Jaundice; neurotoxic; neurotoxicity; Neurotoxins; Newborn Infant; novel; Pathway interactions; Pediatrics; Performance; Phase; Phototherapy; Physiologic Thermoregulation; Positioning Attribute; Postpartum Period; prototype; Public Health; Radial; Recommendation; Research Design; Risk; Rural; Sales; Serum; Skin; Small Business Innovation Research Grant; Sparrows; Staging; Stress; Surface; Technology; Temperature; Testing; Therapeutic; thermostability; Time; tool; Treatment Efficacy; United States; Urine; Visual impairment; Water; Work; World Health Org